Has Robert Zeiger received payments from drug or device companies?

Yes. Drug and device makers reported $162,402 in general payments to Robert Zeiger across 139 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Robert Zeiger did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Robert Zeiger come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Robert Zeiger

Allergy · San Diego, CANPI 1639238249

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $153,912 of the $162,402 with a category attached, or 94.8%. AstraZeneca accounts for 63.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $66,284 and has fallen 96.6% since, to $2,241 in 2025. Among allergy clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$162,402in general payments, 2019–2025

Across 139 payments — averaging $1168.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$104K
Regeneron Healthcare Solutions, Inc.$25K
Astrazeneca UK Limited$12K
Regeneron$9K
Astrazeneca AB$4K
GSK$3K
plus $5K from 5 others

$567,958in research payments, 2019–2025

Across 26 payments — averaging $21,845 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$434K
Astrazeneca UK Limited$125K
Sanofi$6K
Novartis$2K
Sanofi-aventis U.S. LLC$1K

What the payments were for

Consulting fees$153,91295%
Speaking & faculty fees$1,4761%
Travel & lodging$5,0623%
Food & beverage$1,7601%
Education$1920%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	84	$103,644
Regeneron Healthcare Solutions, Inc.	26	$24,818
Astrazeneca UK Limited	10	$12,351
Regeneron	4	$9,382
Astrazeneca AB	2	$3,759
GSK	4	$3,393
Merck	2	$2,823
F. Hoffmann-la Roche AG	1	$1,476
Novartis	1	$545
Genentech, Inc.	4	$192
Sanofi	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FASENRA$75,861
DUPIXENT$33,410
AIRSUPRA$4,296
MK-7264$2,125
XOLAIR$2,021

How this compares

$162,402 in reported general payments places this provider in the 95th percentile of 117 allergy providers in California.

See all allergy providers in California →

Other allergy in San Diego

Sandra ChristiansenSan Diego$74K
Taylor DohertySan Diego$18K
Fang LinSan Diego$3K
Eric MacySan Diego$3K
Joshua JacobsWalnut Creek$1.5M
Warner CarrLaguna Niguel$571K
Bradley ChippsSacramento$571K
Travis MillerRoseville$273K
William BergerMission Viejo$76K
Stephen WongHacienda Heights$50K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →